Corrigendum to "Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3369 patients in the ARCAD database" Eur J Cancer. 2023 Jan;178:162-170 No … ← Female advantage in neoadjuvant pancreatic cancer therapy: is it down to macrophages? Quality of life in sarcoidosis →